Objective: We aimed to develop a quantitative biomarker referred to as basal-luminal score to assess the luminal and basal features in bladder cancer (BCa). Multiparametric MRI (mpMRI)-based radiomics signatures were also developed to preoperatively predict the basal-luminal score.
Methods: Gene Set Variation Analysis was performed to evaluate the basal-luminal score using RNA expression data of gene sets for basal and luminal features. Kaplan-Meier curves with the log-rank test, univariate/multivariate Cox regression analysis and meta-analysis were used to investigate the prognostic value of the basal-luminal score. Gene Set Enrichment Analysis and western blot were used to explore the biology behavior of the basal-luminal score. 111 BCa patients with RNA-sequence data and preoperative mpMRI were collected in our center to construct mpMRI-based radiomics signatures for the prediction of the basal-luminal score.
Results: The basal-luminal score was highly associated with the molecular subtypes of BCa. Patients with high basal-luminal scores had poorer prognoses than patients with low basal-luminal scores in several public data sets, including The Cancer Genome Atlas, IMvigor210, GSE13507, GSE31684, GSE32894 and GSE48277. Hallmarks of multiple oncogenic pathways were significantly enriched in the high basal-luminal group. The support vector machine based on 18 radiomics features achieved the optimal performance in the prediction of the basal-luminal score in both the training (accuracy:85.7%) and validation sets (accuracy:82.4%).
Conclusion: The basal-luminal score is associated with molecular subtypes and prognosis in BCa. Biological functional analysis revealed the oncogenic role of the basal-luminal score. The mpMRI-based radiomics signature may be useful for preoperatively predicting the basal and luminal features in BCa.

Multiparametric MRI-based radiomics signature for preoperative estimation of basal and luminal features in bladder cancer

For 2021, our focus remains: turning new data into your daily practice. The programme will consist of state-of-the-art lectures, case discussions and panel debates. Our faculty is a group of international & multidisciplinary experts.

We will take you on our journey to Ghent and beyond. Prior the congress, we send out case challenges, where you can compare your opinion with peers & experts. These cases will be part of the Global Congresses on Prostate & Bladder Cancer programme during the congress days (12 & 13 October for PROSCA and 14 & 15 October for BLADDR). After these days, you will be updated on prostate & bladder cancer management.